S'abonner

IL-13 and IL-13–induced periostin levels are specifically decreased in patients following endoscopic sinus surgery for chronic rhinosinusitis - 03/05/24

Doi : 10.1016/j.jaci.2023.11.922 
Regan Harmon, BS a, Alexander L. Schneider, MD a, b, Junqin Bai, PhD a, Samuel D. Racette, MD a, Abhita T. Reddy, MD a, Julia H. Huang, DDS, MS a, David S. Lehmann, BS a, Caroline P.E. Price, BA a, Samuel Rodeghiero, BS a, Aditi Agarwal, MD , Jacob G. Eide, MD a, Siyuan Dong, MS c, David B. Conley, MD a, Kevin C. Welch, MD a, Robert C. Kern, MD a, Stephanie Shintani-Smith, MD, MS a, Anju T. Peters, MD, MS a, b, Atsushi Kato, PhD a, b, Whitney W. Stevens, MD, PhD a, b, Lutfiyya N. Muhammad, PhD, MPH c, Robert P. Schleimer, PhD a, b, Bruce K. Tan, MD, MS a, b,
a Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Ill 
b Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill 
c Department of Preventative Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill 

Corresponding author: Bruce K. Tan, MD, MS, Department of Otolaryngology–Head and Neck Surgery, Northwestern University Feinberg School of Medicine, 676 N St. Clair St, Suite 1325, Chicago, IL 60611.Department of Otolaryngology–Head and Neck SurgeryNorthwestern University Feinberg School of Medicine676 N St. Clair StSuite 1325ChicagoIL60611

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Abstract

Background

Type 2 (T2) inflammation plays a pathogenic role in chronic rhinosinusitis (CRS). The effects of endoscopic sinus surgery (ESS) on T2 inflammation are unknown.

Objective

The aim of this study was to compare T2 inflammatory biomarkers from middle meatal (MM) mucus for distinguishing patients with CRS from CRS-free patients, identifying major phenotypes (CRS without nasal polyps [CRSsNP] and CRS with nasal polyps [CRSwNP]), assessing endotypic change, and establishing cross-sectional and longitudinal outcomes in patients undergoing ESS.

Methods

MM mucus samples were collected from patients with CRSsNP and patients with CRSwNP before and 6 to 12 months after ESS and compared with samples from CRS-free control patients. T2 biomarkers were evaluated both continuously and using threshold-based definitions of T2 endotype to identify relationships with patient-reported (based on the 22-Item Sinonasal Outcomes Test and Chronic Rhinosinusitis Patient-Reported Outcomes Measure) and clinician-reported (radiographic and endoscopic) severity. Linear mixed models were developed to analyze clinical variables associated with T2 biomarker levels.

Results

A total of 154 patients with CRS (89 with CRSsNP and 65 with CRSwNP) were enrolled, with a mean interval of 9 months between ESS and follow-up. An analysis of pre-ESS MM mucus samples revealed elevated levels of T2 mediators in patients with CRSwNP versus in patients with CRSsNP and CRS-free controls. Temporally stable correlations between levels of IL-13 and IL-5, levels of periostin and complement 5a, and levels of eosinophil cationic protein (ECP) and eotaxin-3 were observed. On this basis and on the basis of pathologic significance, levels of IL-13, periostin and ECP were further analyzed. After ESS, levels of IL-13 and periostin decreased significantly, whereas ECP levels remained unchanged. Across pre- and post-ESS evaluation, the T2 endotype was associated with radiographic severity but did not predict outcomes. CRSwNP status and African American race were associated with higher levels of IL-13 and periostin, whereas ECP level was higher in patients undergoing extensive surgery.

Conclusion

ESS decreased levels of IL-13 and periostin in the middle meatus. T2 inflammation after ESS was correlated with patient- and clinician-reported severity across phenotypes. Pre-ESS T2 inflammation did not predict post-ESS outcomes.

Le texte complet de cet article est disponible en PDF.

Key words : Chronic rhinosinusitis, nasal polyps, CRSwNP, CRSsNP, endotype, patient-reported outcome measures, biomarker

Abbreviations used : AERD, BSIT, C5a, CCL26, CRS, CRSsNP, CRSwNP, CRS-PRO, ECP, ESS, LM, MLK, MM, OCS, PROM, SNOT-22, T2


Plan


© 2024  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 153 - N° 5

P. 1292-1305 - mai 2024 Retour au numéro
Article précédent Article précédent
  • Accurate determination of house dust mite sensitization in asthma and allergic rhinitis through cytometric detection of Der p 1 and Der p 2 binding on basophils (CytoBas)
  • Lin Hsin, Nirupama Varese, Pei Mun Aui, Bruce D. Wines, Anouk von Borstel, Laurent Mascarell, P. Mark Hogarth, Mark Hew, Robyn E. O’Hehir, Menno C. van Zelm
| Article suivant Article suivant
  • Aggregated eosinophils and neutrophils characterize the properties of mucus in chronic rhinosinusitis
  • Yui Miyabe, Mineyo Fukuchi, Hiroki Tomizawa, Yuka Nakamura, Mitsutoshi Jikei, Yoshinori Matsuwaki, Misaki Arima, Yasunori Konno, Yuki Moritoki, Masahide Takeda, Naoya Tanabe, Hiroshi Shima, Yusuke Shiraishi, Toyohiro Hirai, Nobuo Ohta, Junko Takahata, Atsushi Matsubara, Takechiyo Yamada, Koichiro Asano, Isao Miyairi, Rossana C.N. Melo, Peter F. Weller, Shigeharu Ueki

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.